Two novel cyclic pentapeptides, bingchamides A (1) and B (2), have been isolated from the organic extracts of the mycelium of Streptomyces bingchenggensis. The structures of 1 and 2 were elucidated on the basis of extensive 1D and 2D NMR, as well as HRESI-MS, electrospray ionization-MS, UV and IR spectroscopic data analysis. Bingchamides A (1) and B (2) exhibited in vitro cytotoxicity toward human colon carcinoma cell line HCT-116 with the IC 50 values of 14.1 and 18.0 lg ml À1 , respectively. The bingchamides A (1) and B (2) scaffolds are probably promising structures for the development of new antitumor agents.
INTRODUCTION
In the course of screening for new biologically active compounds from microbial sources, an actinomycete strain, Streptomyces bingchenggensis, was isolated from a soil sample collected in Harbin, China. The fermentation broths of S. bingchenggensis possess not only potent acaricidal and nematocidal activity, but also antitumor activity. In the previous research, we isolated compounds with potent acaricidal and nematocidal activity, milbemycins b 13 , b 14 , a 28 , a 29 , a 30 , secomilbemycins A, B, 1-3 and a novel macrolide compound, ST906 4 with antitumor activity, from S. bingchenggensis. We investigated the fermentation broths of this microorganism in more detail and have isolated two new cyclic pentapeptide compounds, bingchamides A (1) and B (2, Figure 1 ). The structures of 1 and 2 were elucidated on the basis of extensive 1D and 2D NMR, as well as HRESI-MS, electrospray ionization (ESI)-MS, UV and IR spectroscopic data analysis. Bingchamides A (1) and B (2) possessed potent cytotoxicity against human cancer cell lines in vitro, and are structurally related to sansalvamide A (3, Figure 1 ), which is also a potent cytotoxic compound isolated from a marine fungus, Fusarium spp. 5 We describe in this paper the fermentation, isolation, structure elucidation and biological properties of 1 and 2. To evaluate their anticancer activities in vitro, we used the drug-resistant human cancer cell line HCT-116. [6] [7] [8] [9] [10] RESULTS AND DISCUSSION Structural elucidation Compound 1 was obtained as a colorless oil with the UV absorptions at l max of 232 and 275 nm. The molecular formula of 1 was established as C 40 H 51 N 5 O 5 on the basis of HRESI-MS and NMR analysis, which indicated the presence of 18 degrees of unsaturation. The IR absorption at 1651 cm À1 indicated the presence of amide functionalities. In the 13 C NMR spectrum of 1, five signals were observed between d 169 and 174, values that are typically assigned to the carbonyls of a peptide. In total, five 13 C NMR signals between d 51 and 63 were characteristic of the a-carbons of amino acid residues. The assignment of five amide groups accounted for all of the nitrogen, oxygen and five of the degrees of unsaturation required by the molecular formula. A total of 12 signals in the aromatic region of the 13 C NMR spectrum between d 126 and 138 were characteristic of three mono-substituted phenyl groups, and suggested the presence of three phenylalanine (Phe) residues, which accounted for an additional 12 unsaturations, and left one remaining unsaturation, requiring that 1 possesses one ring. Application of 2D NMR techniques ( 1 H-1 H COSY, heteronuclear multiple quantum coherence (HMQC) and heteronuclear multiple bond correlation (HMBC)), which allowed for the identification of all of the amino acid residues of 1, revealed the presence of leucine (Leu), isoleucine (Ile), two phenylalanines (Phe-1 and Phe-2) and one N-Me phenylalanine (N-Me-Phe). Two-and three-bond HMBC correlations from the a-and/or b-protons of each residue to their neighboring carbonyl carbons and the NOESY experiments were useful in assigning the carbonyl signals and in establishing the amino acid sequence of 1 (Figure 2 (Table 1 ). The key NOESY signal between d 5.21 and d 6.77 connected the N-Me-Phe to Leu. The sequence of four amino acid residues (Phe-1, N-Me-Phe, Leu and Ile) was completed. Consequently, the remaining Phe-2 connected with Ile and Phe-1, and was acylated by Ile. Thus, the overall sequence for 1 was established in the only way possible.
The stereochemistry of 1 remained unknown because of the absence of correlation signals of the five a-protons of the five amino acid residues in the NOESY experiment and the poor amount of 1. To confirm the structure of 1 and establish its conformation, chemical synthesis of 1 is ongoing. amino acid residue as 3-(furan-3-yl)-N-Me-alanine (3-(furan-3-yl)-N-Me-Ala). Consequently, the gross structure of 2 was elucidated as the similar sequence of 1 except that the residue of 3-(furan-3-yl)-N-Me-Ala in 2 replaced the residue of N-Me-Phe in 1. A furan ring incorporated into a cyclic peptide structure as a natural product is rare. 11, 12 
Biological activity
We examined the inhibitory activity of bingchamides A (1) and B (2) against the growth of human colon carcinoma cell line HCT-116 using the CCK-8 colorimetric method as described in Methods. Compound 1 and 2 dose-dependently inhibited the growth of HCT-116 cells with IC50 value of 14.1 and 18.0 mg ml À1 , respectively. Natural products are excellent sources of potential new drug leads. These novel structures are important for the development of original therapeutic leads that target new biological pathways. 13 Sansalvamide A is one such natural product (3, Figure 1) . A number of analogs have been made. These sansalvamide A derivatives [6] [7] [8] [9] [10] [14] [15] [16] [17] [18] [19] [20] have shown that they are privileged structures and exhibit potency against multiple targets in numerous cancer cell lines. The examples of potent cytotoxicity against pancreatic, colon, breast, prostate and melanoma cancers clearly indicate the potential of this compound class as a platform useful in targeting these cancers. The structures of bingchamides A (1) and B (2) are similar to sansalvamide A, and they all belong to cyclic pentapeptides. However, there are significant differences among them. This shows that like sansalvamide A, bingchamides A (1) and B (2) scaffolds are probably promising structures for the development of new antitumor agents. 
METHODS

General
Microorganism
The producing organism, S. bingchenggensis, was isolated from a soil sample collected in Harbin, China. S. bingchenggensis has been deposited at the China General Microbiology Culture Collection Center (Accession no: CGMCC1734), Institute of Microbiology, Chinese Academy of Sciences, and we have determined the 16S rDNA sequence (Accession no: DQ449953 in GenBank, National Center for Biological Information).
Fermentation
The seed for preculture was spores. The medium for sporulation contained sucrose (Bei Jing Ao Bo Xing, Beijing, China) 4 g, yeast extract (Bei Jing Ao Bo Xing) 2 g, malt extract (Bei Jing Ao Bo Xing) 5 g and skim milk (Nmyili, Huhehaote, China) 1 g in 1 l water. The pH was adjusted to 7.0 with 1 M NaOH, 20 g of agar was added and this mixture was sterilized at 121 1C for 30 min. The spore suspension was prepared from the agarplates (20 ml) incubated at 28 1C for 7-8 days.
A spore suspension of the culture of strain S. bingchenggensis, 1ml, was transferred to a 250-ml Erlenmeyer flask that contained 25 ml of the seed medium containing sucrose 0. 
Isolation and purification
The fermentation broth (30 l) was filtered. The resulting cake was washed with water, and both filtrate and wash were discarded. Methanol (5 l) was used to extract the washed cake. The MeOH extract was concentrated to approximately 1 l under reduced pressure and the resulting concentrate was extracted three times with an equal volume of EtOAc. The combined EtOAc phase was concentrated under reduced pressure to yield 50 g of oily substances. The residual oily substance was chromatographed on silica gel and eluted with petroleum ether-acetone (95:5-50:50) to give five fractions. The semi-preparative HPLC (Agilent 1100, Zorbax SB-C18, 5 mm, 250Â9.4 mm i.d.) was further applied to obtain pure compounds. The eluates were monitored with a photodiode array detector at 220 nm and the flow rate was 1.5 ml min À1 at room temperature. The fifth fraction (petroleum ether-acetone 1:1) with anticancer activity was separated by semi-preparative HPLC using a solvent of 85% CH 3 CN/H 2 O to afford 1 (11.1 min, 13.0 mg) and 2 (9.8 min, 9.5 mg).
Physico-chemical properties of compounds 1. 
Biological assays
The cytotoxicity of compound on tumor cells was assayed according to the published procedures. 21 Human colon carcinoma cell line HCT-116 was routinely cultured in Dulbecco's Modified Eagle Media containing 10% calf serum at 37 1C for 4 h in a humidified atmosphere of 5% CO 2 incubator. The adherent cells at their logarithmic growth stage were digested, and were inoculated onto 96-well culture plate at a density of 1.0Â10 4 per well for the determination of proliferation. Test samples were added to the medium, and incubation was continued for 72 h. Coloration substrate, cell-counting kit-8 (CCK-8, Dojindo, Kumamoto, Japan), was added to the medium followed by further incubation for 3 h. Absorbance at 450 nm with a 600 nm reference was measured thereafter. Media and DMSO control wells, in which compound was absent, were included in all the experiments to eliminate the influence of DMSO. The inhibitory rate of cell proliferation was calculated by the following formula:
Growth inhibitionð%Þ ¼ ½OD control ÀOD treated =OD control Â100
The cytotoxicity of compound on tumor cells was expressed as IC 50 values (the drug concentration reducing by 50% the absorbance in treated cells, with respect to untreated cells) and was calculated by LOGIT method.
